Lantern Pharma’s (LTRN) N-hydroxy-N(methylacylfulvene)urea was granted FDA orphan designation as a treatment of soft tissue sarcoma, according to a post to the agency’s website.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma establishes India AI center to industrialize RADR platform
- Lantern Pharma announces LP-184 clinical trial met all primary endpoints